AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02026531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-Helium gas
Description: 3-Helium gas for MRI contrast
Study NCT00248040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin continuous infusion
Description: The Investigational Product was administered as an intravenous infusion into a (high flow) central vein or through an arterio-venous fistula, by an infusion pump adequate to provide reliable infusion rates, as per treatment schedule. Total infusion volume did not exceed 500 mL/24 hours. A dose of 2.772 mg/kg body weight/hour was to be administered for 12 hours. Placebo was volume/schedule matched saline.
Study NCT00248040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reparixin intermittent infusion
Description: A dose of 2.244 mg/kg body weight was to be administered over a 30-minute period, followed by a 1.5-hour interval. Twelve doses were to be administered over a total period of 22.5 hours. Placebo was volume/schedule matched saline.
Study NCT00248040 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: placebo was volume/schedule matched saline
Study NCT03221153 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulation techique
Description: The intervention group will be in a simulated case with mock scenarios and interaction by 'acting out' the clinical situation where knowledge and attitudes about safety in hospitalized patients will be assessed.
Study NCT01715324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Growth Hormon
Description: The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering
Study NCT04683614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: 5 mic/kg/hr norepinephrine
Study NCT04683614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Description: early administration of fresh frozen plasma
Study NCT00426413 — intervention group
Intervention type: DRUG
Intervention: pioglitazone
Description: Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
Study NCT00543413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK8141
Description: MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
Study NCT00543413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: MK8141 Pbo tablet once daily. 4 week treatment period.
Study NCT00543413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril 20 mg tablet once daily. 4 week treatment period.
Study NCT01748513 — intervention group
Intervention type: OTHER
Intervention: preoperative venous return optimizing
Description: Preoperative transthoracic echocardiography (TTE) was performed in the awake state before and after volume challenge based on 6ml colloids /kg ideal body weight.
Study NCT02844309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: thalidomide 50-150 mg per night
Study NCT03403283 — intervention group
Intervention type: OTHER
Intervention: 15 subjects with Non Proliferative Diabetic Retinopathy(mild, moderate and severe). 15 subjects with Proliferative Diabetic Retinopathy
Study NCT03403283 — intervention group
Intervention type: OTHER
Intervention: Healthy Controls 15 age matched control subjects
Study NCT02217358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI endoscopy
Description: see in detail description of the study part of the protocol
Study NCT01565824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based support
Study NCT03931369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 MG
Description: Single administration of one pill of 15 MG tolvaptan
Study NCT00851058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief group counseling
Description: Four group counseling sessions and six hours of direct observations of the emergency and trauma services in a busy urban hospital.
Study NCT00851058 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Counseling
Description: Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
Study NCT00851058 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prototypic community service
Description: Two educational session on road safety and 16 hours of volunteering in a local not for profit community service.
Study NCT00851058 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prototypic community service
Description: Four hours education about road safety and 16 hours volunteering at a local not for profit community service
Study NCT04043858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine 2.5 mg tab
Description: Patients receive an oral daily dose of 2.5 mg midodrine if age 7-12 years and receive 2.5 mg twice daily of more than 12 years
Study NCT03323424 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)
Description: According to the usual practice, patients will receive their systemic treatment, composed of :~* Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~* FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~* 5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice.~In addition to the systemic treatment, patients randomized into this experimental group will receive a SBRT of 45Gy in 3 fractions for hepatic and pulmonary metastasis, 27Gy in 3 fractions for bone metastasis and 33 Gy in 3 fractions for intra-cranial metastasis.
Study NCT03323424 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systemic treatment
Description: According to the usual practice, patients will receive their systemic treatment, composed of :~* Taxane + trastuzumab +pertuzumab for metastatic breast cancers;~* FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;~* 5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.~If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice.
Study NCT04652219 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gucy2c cart cells
Description: Patients with advanced malignant gastrointestinal tumors were injected with CART cells
Study NCT01678404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-rituximab
Study NCT01154257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cleaning of teeth with a toothbrush
Description: This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a toothbrush. Cleaning will be twice daily from recruitment until day seven.
Study NCT01154257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cleaning of teeth with a foam swab
Description: This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a foam swab. Cleaning will be twice daily from recruitment until day seven.
Study NCT04527770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Ultrasound guided median nerve hydrodiseection using dexamethasone or midazolam
Study NCT04527770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: intracarpal injection of midazolam and bupivacaine 0.5%
Study NCT00067730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin Alfa (activated)
Study NCT00976404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA + HIV-rAd5 vaccine
Description: 4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)
Study NCT00976404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART intensification (raltegravir)
Description: raltegravir 400 mg PO BID for 56 weeks
Study NCT00976404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART intensification (raltegravir)
Description: raltegravir 400 mg PO BID for 56 weeks
Study NCT00976404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART intensification (maraviroc)
Description: maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
Study NCT00976404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART intensification (maraviroc)
Description: maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
Study NCT02196948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrolysis Percutaneous Therapeutic (EPTE)
Study NCT02196948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Study NCT03363490 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Self-management program
Description: Self-management diary will record the frequency of pain, fatigue and injury of knee joint due to knee OA, if patients maintain proper activities, it will be also recorded by an smart phone APP. Patients diet and intake calorie will also be recorded in the diary，which help clinicians to adjust their diet, control their body weight.
Study NCT03363490 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Neuromuscular exercise therapy
Description: The exercise therapy is basically combined with neuromuscular training and anti resistance training. The aim is to improve the stability of the joints, enhance sensory motor control of lower extremities, reconstruct neutral position line. The exercise mode, frequency, intensity and duration will be adjusted individually through monitoring patient's pain.
Study NCT03363490 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health education
Description: All four groups of patient will receive two times of health education in the first week.
Study NCT03046862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1.12 g iv on D1 every 3 weeks
Study NCT03046862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 75mg iv on D1 every 3 weeks
Study NCT03046862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 iv on D1\& D8 every 3 weeks
Study NCT03046862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 25 mg/m2 iv on D1\& D8 every 3 weeks
Study NCT03419559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN-145
Description: adoptive cell therapy (ACT) with autologous TIL therapy
Study NCT03419559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: PD-L1 antagonist monoclonal antibody
Study NCT01377103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: testerone gel
Description: 5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
Study NCT01377103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01255436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS text reminders
Description: Patients in the intervention arm will receive 2 text messages per week delivered via SMS on randomly chosen days and times during the 12-week study period. The aims of the messages are to remind patients to take their blood pressure medications daily, what the target blood pressure is, and the benefits of daily intake of anti-hypertensive medications.
Study NCT01255436 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patients in the usual care arm will receive the care usually provided by their physicians. This consists of consultations, medical advice, and prescriptions for maintenance medications. They will not be sent any SMS text reminders from the study.
Study NCT00557856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03446962
Description: To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
Study NCT04558294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide
Description: A moderate dose of 100 μg LSD will be administered.
Study NCT04558294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketanserin Placebo
Description: Mannitol capsules instead of capsules containing Ketanserin.
Study NCT04558294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketanserin
Description: A dose of 40 mg Ketanserin will be administered.
Study NCT00916331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subcutaneous indwelling
Description: vacuum drainage is indwelled in subcutaneous layer
Study NCT00916331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraarticular indwelling
Description: vacuum drainage is indwelled in intraarticular space
Study NCT03016494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of DWC20155 and DWC20156
Study NCT03016494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1386 Tab.
Study NCT03683459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemFlow Drug-Eluting Peripheral Balloon Catheter
Description: Medical devices will be applied to the enrolled subjects. The arterial pathway was established, followed by lower limb arteriography, and the auxiliary equipment was selected according to the stenosis of the subject's target lesions, followed by pre-dilation. Patients with residual stenosis ≤70% after pre-dilation and suitable for simple balloon dilation catheter treatment can be enrolled. Select the appropriate size of the experimental drug balloon for expansion, then radiography was used to observe the expansion effect, if necessary, multiple expansion can be conducted, and finally withdraw the instrument and suture the puncture point.
Study NCT00711191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: monoclonal antibody
Description: CP-870,893 intravenous administration \[IV\] on day 3 of 4-week cycles
Study NCT00711191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: gemcitabine 1000 mg/m\^2 intravenous administration \[IV\] q week \[wk\]x3 of 4-week cycles
Study NCT02035267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Study NCT02035267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection.
Study NCT04917016 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma B-HCG levels
Description: Blood sample
Study NCT01817803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemide/no spironolactone
Description: furosemide (doubling previous furosemide dose)
Study NCT01817803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metolazone/no spironolactone
Description: metolazone (add 2.5mg qod)
Study NCT01817803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: furosemid/spironolactone
Description: furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
Study NCT01817803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metolazone/spironolactone
Description: metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
Study NCT00751608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL180
Study NCT00751608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APL180
Study NCT00751608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02309905 — intervention group
Intervention type: DEVICE
Intervention: Telemedicine
Description: Inmates of prisons having telemedicine after implementation of telemedicine
Study NCT00705952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Diet, exercise and behavioural change intervention.
Study NCT02914301 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Babyscripts Prenatal App
Description: The use of a mobile digital app to facilitate certain aspects of standard prenatal care.
Study NCT02914301 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No Mobile App, Usual care
Study NCT01576900 — intervention group
Intervention type: BEHAVIORAL
Intervention: SyBeMeP (Systemized Behavioural Modification education Program)
Description: * Standard video material will be developed to minimize variation of outcomes caused by differences in contents at each trial site.~* Video material will be self-study program for PC with running time around 20 minutes. Contents will cover pathophysiology, diagnosis and treatment process, and be easy to understand for everyone with variety of examples. In treatment part, it will describe general principles of behavioural therapy (Adjustment of timing of fluid intake, Reducing alcohol and caffeine, Improving sleep hygiene including moderate exercise, room temperature, noise and lighting. if necessary, compressive stocking, late afternoon nap and leg elevation would be added)~* During trial, patients will watch SYBeMeP at a specially prepared separate room with computer.~* After watching the video, check-list on take-home message will be recorded by patients at the site to confirm patients' awareness after education.
Study NCT00842491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endostar, cisplatin, capecitabine
Description: Product 1: endostar~Dosing schedule: 15mg daily dose, d1-14~Mode of administration: intravenously
Study NCT00842491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Product 2: capecitabine~Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks~Mode of administration: orally
Study NCT00842491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Product 3: cisplatin~Dosing schedule: 80mg/m2, day 1 of every 3 weeks~Mode of administration: intravenously
Study NCT01432925 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical intervention on Buruli ulcer
Description: Can the need for surgical intervention be avoided by delay of the decision on surgical intervention, comparing the need on surgical intervention from time points of week 8 and week 14 (number of weeks after start of antibiotic treatment with streptomycin/rifampicin).
Study NCT03187392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Injectable Product
Description: 3 cm of Lidocaine- will be injected subcutaneous for 5 minutes before insertion of subcutaneous birth control implant
Study NCT03187392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Topical Cream [LMX]
Description: 3 mg of Lidocaine- will be applied to skin for 5 minutes before insertion of subcutaneous birth control implant
Study NCT03727256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound therapy
Description: Group 1, ultrasound therapy ;1 watt/cm² dose, 1 MHz, 5 minutes
Study NCT03727256 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular electrical stimulation application
Description: Group 2, neuromuscular electrical stimulation application;20 mins/session
Study NCT03544762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FES PET
Description: 18F-FES PET will be performed for each patient. All patients will receive intravenously injection of 5-8 mCi (185-296 MBq) of 18F-FES. PET imaging will be performed on PET/CT system. The 1-frame dynamic data acquisition of thoracic region including the primary tumor will be started immediately after tracer injection. Whole-body PET acquisition from skull base to upper thigh will be started 60 minutes after tracre injection.
Study NCT04030117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACTIVA Bioactive restoration
Description: Removal of Class II decay in second primary molars and placement of ACTIVA restoration.
Study NCT04030117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Compomer restoration
Description: Removal of Class II decay in second primary molars and placement of Compomer restoration.
Study NCT04651842 — intervention group
Intervention type: DEVICE
Intervention: PCI
Description: Acute Insulin Resistance on Myocardial Blush in Non- Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention
Study NCT01950130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative IABC
Description: IABP-Insertion upon inclusion into the trial and admission to the ICU
Study NCT01750229 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Frequency Setting - Sham
Study NCT01750229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1200 Hz
Description: Frequency Setting - 1200 Hz
Study NCT01750229 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3030 Hz
Description: Frequency Setting - 3030 Hz